Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

A genome-wide association study of brain lesion distribution in multiple sclerosis.
Spasticity improvement in patients with relapsing-remitting multiple sclerosis switching from interferon-β to glatiramer acetate: the Escala Study.
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
Study hints of rituximab MS benefit
Glatiramer acetate-induced acute hepatotoxicity in an adolescent with MS.
The Hedgehog pathway promotes blood-brain barrier integrity and CNS immune quiescence.
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.
The role of T cell apoptosis in nervous system autoimmunity.
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
The effect of vitamin a supplementation on biochemical parameters in multiple sclerosis patients.
Integrated analysis of daclizumab HYP pharmacokinetics from three phase 1 studies
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
[Evaluation and quantification of spasticity: a review of the clinical, biomechanical and neurophysiological methods].
Good Early Results for HERV Suppressor in MS
Ofatumumab
The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group.
Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
Sanofi MS drug nears green light after pass-the-parcel marathon
Colestipol May Quickly Eliminate Teriflunomide
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
Immune status following alemtuzumab treatment in human CD52 transgenic mice.
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA

Pages